Article
BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis.
Blood - 2 Nov 2023
Acosta-Medina Aldo A, Kemps Paul G, Zondag Timo C E, Abeykoon Jithma P, Forma-Borst Jelske, Steenwijk Eline C, Feijen Elizabeth A M, Teepen Jop C, Bennani N Nora, Schram Susan M, Shah Mithun V, Davidge-Pitts Caroline, Koster Matthew J, Ryu Jay H, Vassallo Robert, Tobin W Oliver, Young Jason R, Dasari Surendra, Rech Karen, Ravindran Aishwarya, Cleven Arjen H G, Verdijk Robert M, van Noesel Carel J M, Balgobind Brian V, Bouma Gerrit Joan, Saeed Peerooz, Bramer Jos A M, de Groen Ruben A L, Vermaat Joost S P, van de Sande Michiel A J, Smit Egbert F, Langerak Anton W, van Wezel Tom, Tonino Sanne H, van den Bos Cor, van Laar Jan A M, Go Ronald S, Goyal Gaurav, van Halteren Astrid G S
Abstract excerpt
In this retrospective study, BRAF mutation status did not correlate with disease extent or (event-free) survival in 156 adults with Langerhans cell histiocytosis. BRAFV600E was associated with an increased incidence of second malignancies, often comprising hematological cancers, which may be clonally related.
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.